The efficacy and safety of<unk>  were both observed in a Phase III study in monotherapy and clinical studies used in combination with other hypoglycemic agents (6 types) in Japan. One placebo-controlled, double-blind study was carried out at 18 different sites in Korea and 12 in Taiwan. Patients were above 20 and had type 2 diabetes for atlas 12 weeks. They were given an 8-week period to clear their systems of all other drugs (besides metformin). Patients received either 50 mg<unk>  or a placebo. The drugs were identical in all physical forms. The patients were prohibited from using any other anti diabetic drugs, other than metformin. The study ran for 24 weeks along with a 4-week follow-up period. The standard deviation in hemoglobin A1c were −0.94% and −0.47% in the<unk>  and placebo groups, respectively (between-group difference −0.46%, p <0.001). The changes in fasting plasma glucose and bodyweight were also significantly greater in the<unk>  group, with between-group differences of −14.1 mg/dL and −1.24 kg, respectively (both p <0.001). The most common adverse events that appeared were upper respiratory infections and urinary tract infections. From this it was concluded that<unk>  is both efficacious as well as safe. However,<unk>  is currently in Observational Case Control clinical trial to see the long-term (over three years) safety of using<unk> . The estimated completion of this trial is October 2018. * 18 October 2016: Astellas completes a clinical trial for Type-2 diabetes mellitus in Japan prior to October 2016 * 7 September 2016: Astellas Pharma plans a phase III trial for Type-1 diabetes mellitus (Combination therapy) in Japan * 1 August 2016: Phase III clinical trials in type 1 diabetes mellitus (combination therapy) in Japan<unk>  was also in development for type 2 diabetes mellitus in the U.S., Europe and other countries, and three phase II trials were completed in combination with metformin. This was since discontinued.
Ipragliflozin
Ertugliflozin
Liraglutide
Linagliptin
Exenatide
Saxagliptin
Vildagliptin
Sitagliptin